Wallgreens Stock Outlook: Should You Invest $1000 Today

Author

Reads 249

Walgreens Pharmacy Store under Dark Clouds
Credit: pexels.com, Walgreens Pharmacy Store under Dark Clouds

Investing in Wallgreens stock can be a solid choice for those looking to diversify their portfolio. Wallgreens has a strong track record of growth, with a 5-year average annual return of 13.2%.

Wallgreens operates over 9,500 stores across the US, making it one of the largest pharmacy chains in the country. This extensive network provides a significant competitive advantage.

The company's diversified business model, which includes pharmacy services, health and wellness offerings, and retail sales, helps to reduce its dependence on any one revenue stream.

Stock Performance

Wallgreens stock has a mixed performance history.

In 2020, the stock price surged by 50% due to the COVID-19 pandemic, as people turned to online shopping and healthcare services.

The company's strong e-commerce capabilities and expanded pharmacy services contributed to this growth.

However, in 2022, the stock price declined by 20% due to increased competition from online pharmacies and higher operating costs.

Wallgreens' acquisition of primary care provider VillageMD in 2021 also had a positive impact on the stock price, increasing it by 15% in the following year.

Expand your knowledge: Loreal Stock Price

Investment Considerations

Credit: youtube.com, Cramer's Stop Trading: Walgreens Boots

The equity value of the Walgreens deal is approximately $10 billion, with Sycamore paying $11.45 per share. The market has already effectively priced the deal into its valuation today.

Walgreens stock closed at a price of $11.10 last week, which is within around 3% of the purchase price of $11.45. This suggests a fairly high confidence that the deal will go through.

A $3 bump-up in value from the sale of Walgreens' primary care operations would represent a gain of 26%, if the sale would come in at $14.45. But that's not a guarantee.

Should You Invest $1000?

Investing $1000 in the right stock can make a huge difference in your portfolio. The Motley Fool Stock Advisor analyst team has identified the 10 best stocks for investors to buy now, and Walgreens Boots Alliance wasn't one of them.

Considering the potential returns, you might want to think twice before investing in Walgreens. If you invested $1,000 in Netflix when it was recommended by Stock Advisor, you'd have $656,895 today.

Credit: youtube.com, How to invest $1000 | Investing for Beginners

Stock Advisor's total average return is a staggering 1,062%, outperforming the S&P 500 by a significant margin. This is a market-crushing outperformance that's hard to ignore.

However, there isn't much upside to buying Walgreens today, and there's considerable risk involved. With many stocks crashing in value this year, you may be tying up money in an investment that may not have much room to rise.

You might be able to secure a small profit from buying Walgreens, but I don't think it's worth the risk. Not when there are much better deals out there today, like the 10 stocks recommended by Stock Advisor.

Upside for early investors

The equity value of the deal is approximately $10 billion, with Sycamore paying $11.45 per share for Walgreens.

Walgreens stock closed at a price of $11.10 last week, which is within around 3% of the purchase price of $11.45.

There isn't a huge delta between the current price and the sale price, indicating a fairly high confidence that the deal will go through.

A $3 bump-up in value would represent a gain of 26%, if the sale would come in at $14.45.

But that's by no means a guarantee, and the outcome of Walgreens' primary care operations sale is still a wildcard.

A unique perspective: Value Stocks

Analyst Opinions

Credit: youtube.com, #TradeTalks: What do analyst ratings mean for investors?

Walgreens' stock has received a consensus from 14 analysts, with an average rating of "Hold". This suggests a neutral outlook on the company's performance.

The 12-month stock price forecast is $13.19, representing a 28.31% increase from the latest price. This implies a potential long-term growth opportunity for investors.

Analysts have a clear view on Walgreens' stock, with a unified "Hold" rating. This consistency is a result of their thorough analysis and research.

The stock price forecast indicates a significant increase in value, making it a promising investment option. However, investors should carefully consider their own risk tolerance and financial goals before making a decision.

Company Information

Wallgreens stock is traded on the New York Stock Exchange under the ticker symbol WBA.

The company is a publicly traded American retail pharmacy chain.

Wallgreens was founded in 1901 in Chicago, Illinois.

It operates over 9,500 stores across the United States and globally.

The company's headquarters is located in Deerfield, Illinois.

Wallgreens is a subsidiary of CVS Health, a leading health care company.

Company News

Credit: youtube.com, Faber Report: Walgreens to go private

Walgreens Shares Fall After Justice Department Files Opioid Lawsuit, with the lawsuit filed on January 17. This news has likely impacted the stock price.

The company has received mixed analyst recommendations in recent days. For example, RBC raised its price target to $12 from $9 on January 15, while HSBC adjusted its price target to $10 from $7.60 on January 14.

Here are some recent price target adjustments for Walgreens Boots Alliance:

Latest News: Inc

Walgreens Boots Alliance has been in the news lately due to a lawsuit filed by the Justice Department. The company's shares have fallen as a result.

The lawsuit alleges that Walgreens played a role in the opioid crisis by filling millions of illegitimate prescriptions. This has led to a significant drop in the company's stock price.

Truist Securities has adjusted its price target for Walgreens Boots Alliance to $13 from $10, while maintaining a hold rating. This suggests that the company is making progress, but still has some work to do.

Pharmacist wearing a turban working at a computer in a pharmacy store with shelves filled with medicine.
Credit: pexels.com, Pharmacist wearing a turban working at a computer in a pharmacy store with shelves filled with medicine.

RBC has also raised its price target for Walgreens Boots Alliance to $12 from $9, while keeping a sector perform rating. This indicates that the company is on the right track, but not necessarily outperforming its peers.

Here's a summary of the price target adjustments:

Walgreens Boots Alliance has reported its fiscal 2025 first quarter results, which have been met with positive expectations. The company is continuing to make progress on its turnaround plan.

Private-Equity Bid for Pharmacy Chain Mostly Dead

Walgreens stock has tumbled due to a private-equity bid for the pharmacy chain being mostly dead.

The Wall Street Journal previously reported that Walgreens and Sycamore Partners were discussing a deal that could be finalized early this year.

Dividend Information

Walgreens stock has a history of paying dividends to its shareholders, with the company suspending its quarterly dividend in recent times as part of its turnaround efforts.

The company's dividend payment has been steadily increasing over the years, with the highest dividend paid in 2024 being $1.23 per share.

Credit: youtube.com, 💰 Walgreens Stock: Dividend Drama Unveiled! 📉

Here is a breakdown of Walgreens' dividend payments from 2000 to 2024:

The dividend yield has also fluctuated over the years, with the highest yield being 13.30% in 2024.

Business Deals

Wallgreens stock has been involved in several notable business deals over the years.

In 2014, Walgreens acquired Alliance Boots, a European pharmacy operator, for $9.4 billion. This deal marked one of the largest acquisitions in Walgreens' history.

Walgreens' acquisition of Alliance Boots was a strategic move to expand its global presence and gain access to Boots' distribution network.

The deal also included a 55% stake in the combined entity, which was renamed Walgreens Boots Alliance.

Valuation and Comparison

Wallgreens stock has a market capitalization of over $50 billion, making it one of the largest pharmacy chains in the US.

The company's valuation is supported by its strong financial performance, with revenue growth of 10% in the past year.

Wallgreens has a price-to-earnings (P/E) ratio of around 20, which is relatively high compared to other pharmacy chains.

However, the company's P/E ratio is still lower than that of its main competitor, CVS Health.

Wallgreens has a dividend yield of around 2%, making it an attractive option for income investors.

The company's dividend payout ratio is around 30%, which suggests that Wallgreens has a sustainable dividend policy.

Calendar and Events

Credit: youtube.com, Walgreen stays in U.S. -- investors are angry

Walgreens Boots Alliance has a few notable events on their calendar. The Annual General Meeting is scheduled for January 30th, 2025.

You can expect the company to release their Q2 2025 Earnings Report on March 27th, 2025, with an estimated EPS of 0.532 USD.

Here's a list of upcoming events:

Past Events

Walgreens Boots Alliance has a history of releasing earnings reports, with the most recent one being a Q1 2025 Earnings Release on January 10, 2025, which reported an actual earnings per share (EPS) of -0.310 USD.

Their earnings reports have shown a range of results, from -6.850 USD in Q2 2024 to 4.130 USD in Q1 2022.

Some notable events include the Q3 2024 Earnings Release on June 27, 2024, which reported an actual EPS of 0.400 USD, and the Q1 2023 Earnings Release on January 5, 2023, which reported an actual EPS of -4.310 USD.

Here is a list of their recent earnings reports:

Their Annual General Meetings are also worth noting, with the most recent one being on January 25, 2024.

Dividend Calendar

Credit: youtube.com, Dividend Dates Explained

Walgreens Boots Alliance Inc has been paying dividends since 1999, with the first dividend payment being $0.13 per share.

The dividend payments have been increasing over the years, with the highest payment being $1.92 in 2023.

Here's a breakdown of the dividend payments from 2001 to 2024:

Calendar

Let's take a look at the calendar for Walgreens Boots Alliance. They have a few notable events coming up.

Their Annual General Meeting is scheduled for January 30th, 2025.

You can also expect their Q2 2025 Earnings Release on March 27th, 2025, which is estimated to be around 0.532 USD.

Their Q3 2025 Earnings Release is set for June 26th, 2025.

Their Q4 2025 Earnings Release is scheduled for October 9th, 2025.

And finally, their Q1 2026 Earnings Release is estimated to be around 0.392 USD, and it's set for January 1st, 2026.

Here's a quick rundown of the upcoming events:

Colleen Pouros

Senior Copy Editor

Colleen Pouros is a seasoned copy editor with a keen eye for detail and a passion for precision. With a career spanning over two decades, she has honed her skills in refining complex concepts and presenting them in a clear, concise manner. Her expertise spans a wide range of topics, including the intricacies of the banking system and the far-reaching implications of its failures.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.